Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
21 nov. 2019 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Patent covers use of MANF in Glaucoma, Wolfram Syndrome and Retinitis Pigmentosa New York, NY, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC...
Amarantus Announces Positive Pre-Clinical Data for MANF in Wolfram Syndrome Presented at the 79th Annual Scientific Sessions of the American Diabetes Association
18 juin 2019 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
Amarantus Announces Issuance of US Patent No. 10,195,251 Covering MANF Treatment of Wolfram's Syndrome, Retinitis Pigmentosa, and Glaucoma for Subsidiary MANF Therapeutics
13 juin 2019 08h42 HE
|
Amarantus Bioscience Holdings, Inc.
New York, NY, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding...
MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances
05 juin 2018 08h11 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
MANF Therapeutics Announces Publication in Society for Neuroscience eNeuro Journal of Human Ocular Distribution and Animal Photoreceptor Protection Data for MANF
21 mai 2018 08h40 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 21, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
MANF Therapeutics Announces Issuance of Patent in Hong Kong Covering Use of MANF for Treatment of Diabetes and Wolfram's
03 mai 2018 09h15 HE
|
Amarantus Bioscience Holdings, Inc.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire – MANF Therapeutics, Inc., a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) in pre-clinical development...
Amarantus Subsidiary MANF Therapeutics Announces Positive Independent Peer-Reviewed Pre-Clinical Data for MANF in Parkinson’s Disease
29 janv. 2018 09h00 HE
|
Amarantus Bioscience Holdings, Inc.
SAN FRANCISCO, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Via OTC PR Wire -- Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS), a US-based biotechnology holding company with wholly-owned subsidiaries...
Amarantus Subsidiary MANF Therapeutics Announces Issuance of Japanese Patent Covering Therapeutic Use of MANF in Treatment of Parkinson's Disease
20 déc. 2017 09h02 HE
|
Amarantus Bioscience Holdings, Inc.
Issued claims include therapeutic protein, gene therapy and cell therapy applicationsPatent extends MANF Therapeutics' exclusivity for MANF treatment of Parkinson's disease in Japan into 2029 SAN...
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
11 déc. 2017 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
Amarantus BioSciences' CEO Gerald Commissiong to Appear on the Big Biz Radio Show
16 mars 2012 10h13 HE
|
Amarantus BioSciences
SUNNYVALE, Calif., March 16, 2012 (GLOBE NEWSWIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today...